Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy · 2025
The impact of embolization endpoints on the efficacy of uterine artery embolization for adenomyosis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yin Liang, Sun Xingwei, Wu Meijin, Zhang Mingqing, Jing Jian, Bai Xuming, Jin Yong
Аннотация
BACKGROUND: This study aimed to assess how embolization endpoints affect the efficacy of uterine artery embolization (UAE) for adenomyosis.
METHODS: In this single-center retrospective cohort study, patients treated with UAE from 2014-2018 received the standard embolization endpoint (SEE), while those from 2019-2022 received the delayed embolization endpoint (DEE). Clinical outcomes, including embolic microsphere volume, uterine volume, CA125 levels, hemoglobin, menstrual flow, dysmenorrhea, and postoperative complications, were compared between the groups.
RESULTS: At six months post-procedure, all patients showed significant improvement in clinical indicators (p < 0.01). Group DEE used significantly more embolic microspheres than Group SEE (p < 0.01) and achieved greater reductions in CA125, menstrual volume, and dysmenorrhea (p < 0.05). There were no significant differences in postoperative uterine volume, hemoglobin, or complication rates between the groups (p > 0.05).
CONCLUSIONS: UAE is a safe and effective treatment for adenomyosis. Compared to the standard approach, the delayed embolization endpoint provides superior symptom relief and warrants broader clinical adoption.
METHODS: In this single-center retrospective cohort study, patients treated with UAE from 2014-2018 received the standard embolization endpoint (SEE), while those from 2019-2022 received the delayed embolization endpoint (DEE). Clinical outcomes, including embolic microsphere volume, uterine volume, CA125 levels, hemoglobin, menstrual flow, dysmenorrhea, and postoperative complications, were compared between the groups.
RESULTS: At six months post-procedure, all patients showed significant improvement in clinical indicators (p < 0.01). Group DEE used significantly more embolic microspheres than Group SEE (p < 0.01) and achieved greater reductions in CA125, menstrual volume, and dysmenorrhea (p < 0.05). There were no significant differences in postoperative uterine volume, hemoglobin, or complication rates between the groups (p > 0.05).
CONCLUSIONS: UAE is a safe and effective treatment for adenomyosis. Compared to the standard approach, the delayed embolization endpoint provides superior symptom relief and warrants broader clinical adoption.